title: Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats.
abstract: The administration of a high-dose of a serine protease inhibitor is recommended in patients complicated by multiple organ failure (MOF), including adult respiratory distress syndrome (ARDS), induced by acute pancreatitis. The accumulation of polymorphonuclear leukocytes (PMN) in affected organs is considered to be one of the causative factors of MOF. Adhesion to endothelial cells (EC), via adhesion molecules, and the transendothelial migration of PMN is closely associated with the accumulation of PMN. We examined the effects of two serine protease inhibitors, ulinastatin (UT) and gabexate mesilate (GM), on EC-PMN adhesion and transendothelial migration in human umbilical vein EC and 51Cr-labeled PMN in vitro. EC-PMN adhesion, and the expression of intercellular adhesion molecule-1 (ICAM-1) and endothelial cell adhesion molecule-1 (ELAM-1) on EC induced by IL-1 beta and TNF alpha, were reduced by the pretreatment of EC with these inhibitors. The transendothelial migration of PMN stimulated by IL-8 was also inhibited by pretreating PMN with UT or GM. We also examined whether these inhibitors reduced PMN accumulation in the lung in rats with acute pancreatitis induced by a closed duodenal loop. The myeloperoxidase activity in and histological findings of the lung suggested that UT and GM reduced PMN accumulation. In conclusion, serine protease inhibitors may inhibit PMN accumulation in ARDS due to acute pancreatitis.
authors.affiliation: Second Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Okumura
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Fujiyama
authors.forename: T
authors.initials: T
authors.lastname: Bamba
mesh_terms: D000208:Acute Disease; D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000276:immunology / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D016670:Gabexate / Q000008:administration & dosage / Q000494:pharmacology*; D006023:Glycoproteins / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000276:immunology*; D008297:Male; D009102:Multiple Organ Failure / Q000209:etiology / Q000517:prevention & control; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D010195:Pancreatitis / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000517:prevention & control; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D006023:Glycoproteins; D014361:Trypsin Inhibitors; D016670:Gabexate; C028665:urinastatin